TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
An October 20 endocrinology roundup highlighted several studies and industry updates, including a finding that roughly one-quarter of active-duty Army men had a single morning testosterone reading below 300 ng/dL. It also summarized CDC data on menopause symptoms and prescription treatment, and a Reddit analysis of adverse-event terms posted by people reporting retatrutide use; the online reports do not establish drug safety or causation.
An October 20 endocrinology roundup reported that roughly one-quarter of active-duty U.S. Army men had a single morning testosterone reading below 300 ng/dL, while separate updates covered menopause symptoms, GLP-1 medicines and online reports of retatrutide side effects. The items summarize studies and company developments, but they do not establish that one low testosterone test diagnoses a disorder or that Reddit posts can determine a drug’s safety.
The Army finding, published in JAMA, was based on a single morning testosterone concentration below 300 ng/dL, a commonly used threshold for low testosterone. The roundup did not provide the study’s sample size, participants’ age distribution, repeat-test results or the proportion who had symptoms. The reported share is a finding about test results in the studied group, not by itself a clinical diagnosis of testosterone deficiency.
A CDC report found that nearly half of U.S. women ages 40 to 60 reported menopausal symptoms in 2025; 15.6% of that group were taking prescription medication for those symptoms. Separately, Novo Nordisk said post-hoc analyses of a phase III trial found an average 25% weight loss among women receiving investigational semaglutide plus cagrilintide, with similar results reported across pre-, peri- and postmenopausal stages. The company’s account concerns a trial analysis, not a general treatment recommendation.
In a JAMA Network Open analysis of Reddit posts by users reporting retatrutide use, frequently appearing adverse-event terms included appetite increases, fatigue, increased energy, insomnia, increased heart rate and muscle-related symptoms. Retatrutide is described in the source material as an unapproved weight-loss drug. The roundup also cited a meta-analysis linking greater weight loss from GLP-1 receptor agonists and emerging multi-hormone receptor modulators with larger blood-pressure reductions, as well as research on depression and anxiety among adults with type 1 diabetes.
What the Findings Can Tell Patients
Together, the reports show how evidence about hormone levels, menopause care and obesity medicines is being generated through different methods: a clinical measurement study, population health reporting, trial analyses and social-media posts. Those methods answer different questions. In particular, the Army result draws attention to low readings but does not show how many men had persistent low levels or related symptoms, while online retatrutide reports can flag experiences for further study but cannot establish how often they occur among all users.
The menopause figures offer a snapshot of reported symptoms and prescription use in a defined age group and year. They may help readers understand the scale of reported symptoms, but the supplied summary does not say which medicines were used, why some women did not take prescription treatment, or whether use reflects access, preference or clinical need. The combination-drug results are also preliminary in the sense that they come from post-hoc trial analyses reported by the manufacturer; the roundup does not provide details needed to compare benefits and risks across menopause stages.
men's testosterone booster supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the October Findings Differ
The roundup combined developments from several publications and news outlets rather than reporting one unified study. Its items included findings attributed to JAMA, the CDC, Annals of Internal Medicine and eClinicalMedicine, alongside reports from CNN, CNBC and FierceBiotech. Each item has a different population, design and level of evidence, so the findings should not be treated as directly comparable.
Other developments included Walmart’s plan to cover more than 250 prescription drugs at no cost for employees in 2027, including some insulins and GLP-1 drugs for diabetes; Verdiva Bio’s decision to end a phase II study of a once-weekly oral GLP-1 candidate, citing “market evolution”; and a collaboration between Zealand Pharma and Generate Biomedicines to use AI in developing protein-based therapies for obesity and metabolic diseases. These announcements provide industry context, but the roundup does not report results from the collaboration or explain the commercial decision behind Verdiva’s move beyond the company’s stated reason.
“Roughly a quarter of active-duty U.S. Army men had a single morning testosterone concentration under 300 ng/dL.”
— MedPage Today, summarizing the JAMA study
As an affiliate, we earn on qualifying purchases.
Limits of Tests and Online Reports
The supplied roundup does not give enough detail to assess the Army study’s design, sample size, or whether participants with low readings had repeat testing or symptoms. A single result below a commonly used cutoff should not be read as evidence that every person in that group has a diagnosed condition. The underlying study would be needed to clarify how the researchers interpreted the measurements.
The Reddit analysis also has clear limits: people posting about a drug are not necessarily representative of all users, and posts do not establish that a medicine caused a reported symptom. The source summary provides no rates of adverse events, comparison group or clinical verification. It is also unclear from the roundup how the menopause medication statistic was defined, what prescriptions it included, and what the full trial data show for the semaglutide-cagrilintide analysis.
As an affiliate, we earn on qualifying purchases.
Full Studies and 2027 Coverage Plans
Readers seeking clinical detail will need the underlying publications, including the JAMA Army study, CDC report and Reddit analysis, rather than relying only on the short roundup. Further trial reporting would be needed to evaluate the semaglutide-cagrilintide results and the blood-pressure findings, including study methods, safety data and comparisons between groups. The source material does not give publication or regulatory milestones for retatrutide.
Walmart’s announced employee drug coverage is planned for 2027; the roundup does not specify an exact start date or list every covered medicine. The AI drug-development collaboration and Verdiva study cancellation may also produce further company updates, but no next research milestones were supplied. Until additional evidence is available, the findings and announcements should be understood within the limits stated by their sources.
As an affiliate, we earn on qualifying purchases.
Key Questions
Does one low testosterone reading mean an Army man has low testosterone?
No. The report describes a single morning reading below 300 ng/dL, not a diagnosis for every person measured. The roundup does not say how many participants had repeat tests or symptoms.
What did the CDC report say about menopause symptoms?
Nearly half of U.S. women ages 40 to 60 reported menopausal symptoms in 2025. The CDC report also found that 15.6% of that group were taking prescription medication for those symptoms.
Do Reddit posts show that retatrutide causes the listed side effects?
No. The analysis counted adverse-event terms in posts by people reporting retatrutide use. Social-media posts cannot establish causation or show how common the symptoms are among all users.
Is retatrutide approved for weight loss?
The source material describes retatrutide as an unapproved weight-loss drug. It does not provide further regulatory details or a timeline for any decision.
When does Walmart plan to cover the listed drugs for employees?
Walmart plans to cover more than 250 prescription drugs in 2027 at no cost for employees, including some insulins and GLP-1 drugs for diabetes. The roundup does not provide an exact start date or a complete drug list.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
